Literature DB >> 32163847

Quantitative magnetic resonance imaging (q-MRI) for the assessment of soft-tissue sarcoma treatment response: a narrative case review of technique development.

Brandon K K Fields1, Darryl Hwang2, Steven Cen2, Bhushan Desai2, Mittul Gulati3, James Hu4, Vinay Duddalwar2, Bino Varghese2, George R Matcuk5.   

Abstract

Soft-tissue sarcomas are a heterogeneous class of tumors that exhibit varying degrees of cellularity and cystic degeneration in response to neoadjuvant chemotherapy. This creates unique challenges in the radiographic assessment of treatment response when relying on conventional markers such as tumor diameter (RECIST criteria). In this case series, we provide a narrative discussion of technique development for whole tumor volume quantitative magnetic resonance imaging (q-MRI), highlighting cases from a small pilot study of 8 patients (9 tumors) pre- and post-neoadjuvant chemotherapy. One of the methods of q-MRI analysis (the "constant-cutoff" technique) was able to predict responders versus non-responders based on percent necrosis and viable tumor volume calculations (p = 0.05), respectively. Our results suggest that q-MRI of whole tumor volume contrast enhancement may have a role in tumor response assessment, although further validation is needed.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neoadjuvant chemotherapy; Percent necrosis; Quantitative magnetic resonance imaging; Soft-tissue sarcoma; Viable tumor volume

Year:  2020        PMID: 32163847     DOI: 10.1016/j.clinimag.2020.02.016

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  1 in total

1.  Whole-tumor 3D volumetric MRI-based radiomics approach for distinguishing between benign and malignant soft tissue tumors.

Authors:  Brandon K K Fields; Natalie L Demirjian; Darryl H Hwang; Bino A Varghese; Steven Y Cen; Xiaomeng Lei; Bhushan Desai; Vinay Duddalwar; George R Matcuk
Journal:  Eur Radiol       Date:  2021-04-23       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.